This Core will support the Projects with both standard MLR monitoring and flow cytometry, and advanced technology including immune cell subset assays by CyTOF analysis, and T cell clonal repertoire assays by high throughput sequencing of TCR genes from appropriate T cell populations, and mRNA expression in DC populations by RNAseq. The Core will support both preclinical models in Projects 2-3 by analyzing mouse cells, and the clinical study in Project 1 by analyzing human cells. In the case of CyTOF, staining of cells for up to 40 targets simultaneously using heavy metal conjugated mAbs and analysis by spectroscopy is expected to lead to the identification of new subsets of adaptive and innate immune cells that will provide additional insights into cells that contribute to tolerance in the preclinical and clinical studies. In the case of high throughput sequencing, alloreactive T cell clones will be identified and purified from pretransplant MLR cultures with recipient responder cells and donor stimulator cells. Clonal frequencies will be determined in recipients before and after tolerance induction to search for evidence of clonal deletion. In addition, the breadth of the T cell clonal repertoire will be examined to study long term immune reconstitution.
The Scientific Core will utilize both standard methods and new techniques to support all Projects. A new method that enables rapid sequencing of T cell receptor genes will be used to analyze T cell recognition of antigens in donor transplants. In addition, a CyTOF instrument will be used to analyze immune cells with improved precision such that new subsets of these cells can be identified that contribute to tolerance of transplants.
|Kawai, Tatsuo; Leventhal, Joseph; Wood, Kathryn et al. (2018) Summary of the Third International Workshop on Clinical Tolerance. Am J Transplant :|
|Scandling, John D; Busque, Stephan; Lowsky, Robert et al. (2018) Macrochimerism and clinical transplant tolerance. Hum Immunol 79:266-271|
|Simonetta, Federico; Alvarez, Maite; Negrin, Robert S (2017) Natural Killer Cells in Graft-versus-Host-Disease after Allogeneic Hematopoietic Cell Transplantation. Front Immunol 8:465|
|Zhang, Hong; Gregorio, Josh D; Iwahori, Toru et al. (2017) A distinct subset of plasmacytoid dendritic cells induces activation and differentiation of B and T lymphocytes. Proc Natl Acad Sci U S A 114:1988-1993|
|Chen, Yi-Bin; Efebera, Yvonne A; Johnston, Laura et al. (2017) Increased Foxp3+Helios+Regulatory T Cells and Decreased Acute Graft-versus-Host Disease after Allogeneic Bone Marrow Transplantation in Patients Receiving Sirolimus and RGI-2001, an Activator of Invariant Natural Killer T Cells. Biol Blood Marrow Transplant 23:625-634|
|Pierini, Antonio; Nishikii, Hidekazu; Baker, Jeanette et al. (2017) Foxp3+ regulatory T cells maintain the bone marrow microenvironment for B cell lymphopoiesis. Nat Commun 8:15068|
|Mavers, Melissa; Maas-Bauer, Kristina; Negrin, Robert S (2017) Invariant Natural Killer T Cells As Suppressors of Graft-versus-Host Disease in Allogeneic Hematopoietic Stem Cell Transplantation. Front Immunol 8:900|
|Hongo, David; Tang, Xiaobin; Zhang, Xiangyue et al. (2017) Tolerogenic interactions between CD8+ dendritic cells and NKT cells prevent rejection of bone marrow and organ grafts. Blood 129:1718-1728|
|Du, Jing; Paz, Katelyn; Thangavelu, Govindarajan et al. (2017) Invariant natural killer T cells ameliorate murine chronic GVHD by expanding donor regulatory T cells. Blood 129:3121-3125|
|Revelo, Xavier S; Ghazarian, Magar; Chng, Melissa Hui Yen et al. (2016) Nucleic Acid-Targeting Pathways Promote Inflammation in Obesity-Related Insulin Resistance. Cell Rep 16:717-30|
Showing the most recent 10 out of 70 publications